LOCALISED MELANOMA RESECTED: ADJUVANT THERAPY FOLLOWED BY SYSTEMIC RELAPSE

CLINICAL CASE PRESENTATION

Rebecca Lee
The Christie NHS Foundation Trust
The University of Manchester
United Kingdom
DISCLOSURE
Research funding and speaker fee Bristol Myers Squibb
Clinical case 1 BRAF MUTANT MELANOMA

- Female in 20s, no comorbidities

**Initial presentation:** T4b N2a M0, stage IIIC melanoma

- **May-Sept 2018:** primary melanoma right posterior shoulder (5.8 mm, ulcerated, mitoses 7 per mm²), WLE + SLNB right axilla (2/4 lymph nodes positive, no extracapsular extension). Right axillary node clearance (0/26 lymph nodes involved)

- **Oct 2018:** Restaging CT scan – subcutaneous nodules right scapula. Biopsy = melanoma.
  
  PET CT scan x 2 nodules right scapula, no distant metastases

- **Dec 2018:** Complete surgical resection. Histology = 2 deep subcutis lymph nodes containing melanoma (clear margins). Repeat CT scan clear
QUESTION 1.

What adjuvant therapy would you offer this patient?

1. Nivolumab 3mg/kg every 2 weeks for 1 year

2. Dabrafenib 150mg twice daily plus trametinib 2mg once daily for 1 year

3. Pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks for 1 year

4. No treatment
Clinical case 1 continued

- **Dec 2018**: commenced on adjuvant single agent nivolumab immunotherapy

- **Jan 2019**: Developed chest tightness and palpitations after three cycles
QUESTION 2.
What could likely be the cause of her symptoms?

1. Atrial fibrillation
2. Hypothyroidism
3. Hyperthyroidism
4. Anxiety
Clinical case 1 cont.

Relapse on adjuvant immune therapy

- **Jun 2019**: Following 12 cycles developed a further hard lump right shoulder. FNA done and confirmed melanoma.

- **Jul 2019**: PET CT scan showed subcutaneous lesion overlying the right scapula and a lytic lesion in the C3 vertebral body.

FNA, fine needle aspiration; PET CT, positron emission tomography-computed tomography
QUESTION 3.

What systemic therapy would you offer this patient?

1. Ipilimumab plus nivolumab

2. BRAF/MEK targeted therapy

3. Clinical trial
Clinical case 1 cont.

- **Jul 2019**: commenced on encorafenib binimetinib and had radiotherapy to C3 lesion
Clinical case 2  BRAF WILD TYPE MELANOMA

Patient in 50s, no comorbidities

- **Initial presentation:** T2a N3a M0, stage III C melanoma
- **May 2017:** primary melanoma excised from right arm (1.5 mm Breslow, non-ulcerated)

- **Aug 2017:** SLNB = positive with a 1 mm deposit

- **Nov 2017:** Axillary lymph node clearance - 3 out of 26 lymph nodes involved (upstaging patient from IIIA to IIIC)
QUESTION 1.
What adjuvant therapy would you offer this patient?

1. Nivolumab 3mg/kg every 2 weeks for 1 year

2. Dabrafenib 150mg twice daily plus trametinib 2mg once daily for 1 year

3. Pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks for 1 year

4. No treatment
Clinical case 2 continued

- **Jan 2018**: commenced adjuvant immunotherapy treatment within the CHECKMATE-915 study (ipilimumab+nivolumab vs. nivolumab)

**Relapse on adjuvant immune therapy**

- **Nov 2018**: PET scan showed a right lung nodule, right hilar lymph node and right femoral head lesion. Patient PS0, asymptomatic.
- Patient unblinded (received nivolumab)

PET, positron emission tomography
QUESTION 2.
What therapy would you offer this patient?

1. Ipilimumab 3mg/kg plus nivolumab 240mg 2wk/480mg 4wk

2. Ipilimumab 1mg/kg plus nivolumab 240mg 2wk/480mg 4wk

3. Ipilimumab 3mg/kg

4. Chemotherapy e.g. dacarbazine

5. Clinical trial
Clinical case 2 continued

- **Dec 2018**: Started ipilimumab + nivolumab. EBUS of right hilar lymph node - confirmed *BRAF* wild type melanoma

- **Jan 2019**: After x 2 cycles of treatment, developed a raised AST of 109 (G2) and high free T4 of 30 pmol/L (normal =10-22 pmol/L). Cycle 3 of ipi + nivo deferred

- **Feb 2019**: Proceeded with cycle 3. Subsequently developed grade 2 colitis - treated with i.v. methyl prednisolone 1mg/kg followed by oral prednisolone to which responded

AST, aspartate transaminase; EBUS, endobronchial ultrasound; i.v., intravenous
Clinical case 2 continued

- **Apr 2019**: Started nivolumab maintenance
- **May 2019**: Re-admission with diarrhoea and recommenced on steroids, however stool culture showed campylobacter infection
- **June 2019**: PET scan showed mixed response to therapy – hilar node responding, slight enlargement of right lung base nodule
- **Aug 2019**: Restarted nivolumab maintenance

PET, positron emission tomography
Thank you